

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB Number: 3235-0287
 Estimated average burden hours per response: 0.5

| | | | | | | | | |
|--|-----------|--------------|---|--|--|--|--|--|
| 1. Name and Address of Reporting Person* Farrell, Michael J. | | | 2. Issuer Name and Ticker or Trading Symbol RESMED INC [RMD] | | | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) | | |
| (Last) RESMED INC. | (First) | (Middle) | 3. Date of Earliest Transaction (Month/Day/Year) 02/07/2025 | | | Director <input checked="" type="checkbox"/> Officer (give title below) 10% Owner Chief Executive Officer | | |
| 9001 SPECTRUM CENTER BLVD | | | 4. If Amendment, Date of Original Filed (Month/Day/Year) | | | 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person | | |
| (Street) SAN DIEGO | CA | 92123 | | | | | | |
| (City) | (State) | (Zip) | | | | | | |

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | | | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct(D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|--|--------------------------------|---|--|------------|----------------|---|---|---|
| | | | Code | V | Amount | (A) or (D) | Price | | | |
| ResMed Common Stock | 02/07/2025 | | M (1) | | 8,009 | A | \$101.64 | 463,481 | D | |
| ResMed Common Stock | 02/07/2025 | | S (1) | | 8,009 | D | \$236.772 (2) | 455,472 | D | |
| ResMed Common Stock | | | | | | | | 0 | I | Lisette and Michael Farrell Foundation |
| ResMed Common Stock | | | | | | | | 2,090 | I | Lisette and Michael Farrell Family Trust |

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr.3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | | 6. Date Exercisable and Expiration Date (Month/Day/Year) | | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | |
|---|--|--------------------------------------|--|--------------------------------|---|--|-----|--|-----------------|---|--|--|---|--|-------|
| | | | | Code | V | (A) | (D) | Date Exercisable | Expiration Date | | | | | | Title |
| ResMed Common Stock Options | \$101.64 | 02/07/2025 | | M | | 8,009 | | 11/11/2019 (3) | 11/14/2025 | ResMed Common Stock | 8,009 | \$0 | 72,083 | D | |

Explanation of Responses:

1. The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024.
2. This transaction was executed in multiple trades at prices ranging from \$235.74 - \$238.67 The price reported above reflects the weighted average sale price.
3. Represents date options first become exercisable. Options vest 1/3 per year.

Michael J. Farrell, Chief Executive Officer

** Signature of Reporting Person

02/10/2025

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

personal use only